Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended that Keytruda's coming loss of ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire Intra-Cellular Therapies, a company whose main asset has the potential to ...